Subject: Fwd: Synergy Over Maximalism: The Part of Stacking Nobody Talks About
From: [email-masked]
To: "[email-masked]" <[email-masked]>
Date: Wed, 25 Mar 2026 12:17:01 -0400

---------- Forwarded message ----------
From: Derek from Peptide Price <[email-masked]>
Date: Mar 25, 2026 at 11:46 AM -0400
To: [email-masked]
Subject: Synergy Over Maximalism: The Part of Stacking Nobody Talks About

> A lot of you have seen the energy protocol.
> ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     ͏     
> Forwarded this email? Subscribe here for more
> Synergy Over Maximalism: The Part of Stacking Nobody Talks About
> Derek
> Mar 25
>
> READ IN APP
>
> A lot of you have seen the energy protocol. And a lot of you have messaged me some version of the same question: “Is that protocol not enough? Why aren’t the research protocols higher?”
> Let me break down exactly why — because understanding this will change how you approach stacking research compounds in general
> Upgrade to paid
> First, What Are These Compounds Actually Doing in Research?
> Before we talk about research protocol strategy, you need to understand what each of these compounds does at the cellular level in research contexts. Don’t worry — keeping it simple.
> Mitochondria are the power plants of cells. They take in nutrients and convert them into ATP — the actual energy currency cells run on. When mitochondrial function declines, everything suffers: energy, cognition, recovery, metabolism. That’s the target these compounds are being researched against.
> Here’s how each compound in the protocol addresses that:
> SS-31 (Elamipretide) SS-31 works directly at the inner mitochondrial membrane in research models. It binds to a molecule called cardiolipin, which is critical for keeping the electron transport chain — the actual ATP-production machinery — running efficiently. Think of cardiolipin like the structural scaffolding that holds the assembly line together. When it degrades, the whole process gets sloppy and produces a lot of oxidative waste (free radicals) instead of clean energy. SS-31 has been shown in research to stabilize that scaffolding and reduce oxidative leakage.
> MOTS-c MOTS-c is a peptide encoded directly within mitochondrial DNA — which makes it unusual. In research, it acts as a signaling molecule that activates AMPK, one of the master regulators of cellular energy balance. When AMPK is activated, cells demonstrate improved utilization of glucose and fatty acids as fuel, mitochondrial biogenesis (the creation of new mitochondria) is promoted, and metabolic efficiency improves. Research suggests MOTS-c essentially sends a signal from the mitochondria to the rest of the cell: get more efficient.
> NAD+ NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that sits at the center of energy metabolism in research models. It’s the electron carrier that shuttles energy through the electron transport chain. It also activates sirtuins — proteins that regulate mitochondrial health, DNA repair, and cellular stress responses. NAD+ levels decline significantly with age in research subjects, and when they drop, mitochondrial function follows. Restoring NAD+ in research replenishes a core substrate the whole system depends on.
> SLU-PP-332 SLU-PP-332 is an ERR (estrogen-related receptor) agonist being studied in research settings. ERRs are transcription factors that regulate the genes responsible for mitochondrial biogenesis and oxidative metabolism. Activating them in research models essentially signals cells to build more mitochondria and upregulate the machinery that oxidizes fat for fuel. Early research has shown significant improvements in exercise endurance and metabolic output through this pathway.
> So Why Don’t You Just Max All of Them in Research?
> Here’s where the synergy piece comes in.
> Look at what these four compounds are collectively doing in research:
>
> • > SS-31 is protecting and optimizing existing mitochondria at the membrane level
> • > MOTS-c is signaling cells to increase metabolic efficiency and build new mitochondria
> • > NAD+ is replenishing the core substrate the electron transport chain runs on
> • > SLU is activating the genes that drive mitochondrial biogenesis and fat oxidation
>
> These pathways are overlapping and reinforcing each other simultaneously in research models. When all four are administered together in a research context, mitochondrial function is being addressed from multiple angles at once. The combined effect observed in research is meaningfully greater than any single compound alone.
> That’s synergy. And synergy means you don’t need to push each individual compound to the protocol you’d use if it were the only thing in the research stack.
> The Cagri + Tirz Analogy
> Let me make this concrete with an analogy most of you will immediately understand.
> Imagine researching Cagrilintide and Tirzepatide together in the same RS. Both suppress appetite through different mechanisms — Cagrilintide through amylin receptor agonism, Tirzepatide through GIP and GLP-1 receptor agonism. They overlap in observed outcome even if the pathways differ.
> Would you run each one at the full protocol you’d use if it were the only compound being researched in that RS?
> Of course not. If you did, you’d overshoot. The RS would experience far more appetite suppression than the research calls for, you’d lose the ability to understand which compound is driving which response, and you’d have no clean way to adjust.
> The right approach: introduce one compound, establish a baseline in the RS, then layer in the second and gauge the additive effect before making any adjustments.
> Mitochondrial peptides follow the same logic. If SS-31, MOTS-c, NAD+, and SLU are all pushing mitochondrial output upward simultaneously in the RS, running each at its individual maximum protocol is redundant at best and counterproductive at worst. You lose signal, you lose control, and you’re not using the synergy to your advantage — you’re overloading the system.
> The Right Mindset for Any Overlapping Research Stack
> This principle applies across the entire research space anywhere mechanisms overlap:
>
> • > GH secretagogues stacked together (CJC, Ipamorelin, GHRP-2, etc.)
> • > Multiple GLP-1 pathway compounds in the same RS
> • > Cognitive peptides hitting overlapping neurological targets
> • > Healing peptides with shared anti-inflammatory mechanisms
>
> Whenever you’re stacking compounds that share a target or outcome in a research context, the protocol for each individual compound should come down. The synergy is doing work that higher individual protocols would be doing if run solo. Don’t pay twice for the same effect.
> The Full Energy Protocol
> If you haven’t seen it yet, I broke down the complete energy research protocol — including compounds, protocols, and the reasoning behind the stack — over on Substack. All compounds are for research use only, not for human consumption.
> Read it here: https://derekpruski.substack.com/p/unlimited-energy-guide-breaking-down?r=4jq1x8
> Where any individual RS lands within that framework will vary. Some research contexts will find the starting point sufficient. Others may build gradually over time. There is no universal answer.
> Start low. Build deliberately. Let the stack do what it’s designed to do.
> Upgrade to paid
> You're currently a free subscriber to Peptide Price. For the full experience, upgrade your subscription.
> Upgrade to paid
>
> Share
>
>
> Like
> Comment
> Restack
>
> © 2026 Derek Pruski
> 548 Market Street PMB 72296, San Francisco, CA 94104
> Unsubscribe